The Transthyretin Protein and Amyloidosis - an Extraordinary Chemical Biology Platform

被引:2
|
作者
Hammarstrom, Per [1 ]
机构
[1] Linkoping Univ, IFM, Dept Phys Chem & Biol, Linkoping, Sweden
基金
瑞典研究理事会;
关键词
D O I
10.1002/ijch.202300164
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The amyloidoses are diseases caused by accumulation of amyloid fibrils from over 40 different human misfolded proteins in various organs of the body depending on precursor protein. Amyloidogenesis is a self-perpetuating reaction with deleterious consequences causing degeneration in cells and organs where depositions occur. Transthyretin, TTR, is an amyloidogenic protein causing sporadic disease from the wild-type protein during aging and from numerous different autosomal dominant familial mutations at earlier ages depending on the sequence of the hereditary variant. Until recently the disease process was poorly understood, and therapies were scarce. Over the past decades, spurred by clinical data, using chemical biology research, the mechanisms of TTR production and misfolding have been elucidated affording almost complete coverage of the TTR amyloidogenesis pathway to be targeted. This translational science success has provided a plethora of therapeutic options for the TTR amyloidoses providing an inspiring example for success in previously intractable diseases. image
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Transthyretin Cardiac Amyloidosis
    Mankad, Anit K.
    Shah, Keyur B.
    CURRENT CARDIOLOGY REPORTS, 2017, 19 (10)
  • [22] Transthyretin Cardiac Amyloidosis
    Anit K. Mankad
    Keyur B. Shah
    Current Cardiology Reports, 2017, 19
  • [23] Hereditary transthyretin amyloidosis
    Hund, E.
    NERVENARZT, 2014, 85 (10): : 1291 - 1297
  • [24] Transthyretin stabilization by Tafamidis in patients with transthyretin amyloidosis
    Merlini, G.
    Coelho, T.
    Judge, D. P.
    Plante-Bordeneuve, V.
    Kelly, J. W.
    Lombardo, I.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 781 - 781
  • [25] Renal Involvement in Transthyretin Amyloidosis: The Double Presentation of Transthyretin Amyloidosis Deposition Disease
    Fenoglio, Roberta
    Baldovino, Simone
    Barreca, Antonella
    Bottasso, Emanuel
    Sciascia, Savino
    Sbaiz, Luca
    Papotti, Mauro
    Roccatello, Dario
    NEPHRON, 2022, 146 (05) : 481 - 488
  • [26] CARDIAC BIOMARKERS IN PATIENTS WITH TRANSTHYRETIN AMYLOIDOSIS AS DOCUMENTED IN THAOS: THE TRANSTHYRETIN AMYLOIDOSIS SURVEY
    Maurer, Mathew S.
    Kristen, Arnt
    Rapezzi, Claudio
    Suhr, Ole
    Kolluri, Sheela
    Damy, Thibaud
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (10) : E1244 - E1244
  • [27] Transthyretin amyloidosis: a little history of hereditary amyloidosis
    Benson, Merrill D.
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2017, 24 : 76 - 77
  • [28] Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage
    Law, Steven
    Petrie, Aviva
    Chacko, Liza
    Cohen, Oliver C.
    Ravichandran, Sriram
    Gilbertson, Janet A.
    Rowczenio, Dorota
    Wechalekar, Ashutosh
    Martinez-Naharro, Ana
    Lachmann, Helen J.
    Whelan, Carol J.
    Hutt, David F.
    Hawkins, Philip N.
    Fontana, Marianna
    Gillmore, Julian D.
    ESC HEART FAILURE, 2020, 7 (06): : 3942 - 3949
  • [29] Investigation into thiol conjugation of transthyretin in hereditary transthyretin amyloidosis
    Suhr, O
    Ando, Y
    Ohlsson, PI
    Olofsson, A
    Andersson, K
    Lundgren, E
    Ando, M
    Holmgren, G
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1998, 28 (08) : 687 - 692
  • [30] Emerging Therapies for Transthyretin Amyloidosis
    Tsoi, Melissa R.
    Lin, Jeffrey H.
    Patel, Ayan R.
    CURRENT ONCOLOGY REPORTS, 2023, 25 (06) : 549 - 558